At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 226 enrolled
Drug / intervention
Sublingual immunotherapy +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomised, Double-blind, Placebo-controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLITone Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis
In Brief
A Phase 3 clinical trial evaluating Sublingual immunotherapy and Placebo for Allergy. Completed, enrolled 226 participants across 1 site.
Detailed Summary
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedApr 2006
Primary CompletionAug 2006
Study CompletionJan 2007
TodayJul 2026
First PostedApr 4, 2006
Enrollment StartJun 1, 2005
Primary CompletionAug 1, 2006
Study CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.2 years ago
Interventions
Sublingual immunotherapybiological
once daily intake of sublingual drops
Placebobiological
once daily intake of sublingual drops